1137

FITC标记的磷酸化间变型淋巴瘤激酶抗体

2017-5-3


                                   FITC标记的磷酸化间变型淋巴瘤激酶抗体                                                                                                                                                
英文名称Anti-phospho-ALK (Tyr1586)/FITC
中文名称:FITC标记的磷酸化间变型淋巴瘤激酶抗体
别    名ALK (Phospho-Tyr1586); ALK(phospho-Y1586); p-ALK(Tyr1586); p-ALK(Y1586); ALK tyrosine kinase receptor precursor; ALK/EML4 fusion gene, included; ALK/NPM1 fusion gene, included; anaplastic lymphoma kinase (Ki-1); Anaplastic lymphoma kinase; Anaplastic lymphoma kinase Ki 1; Anaplastic lymphoma kinase Ki1; Anaplastic lymphoma kinase p80 CD 246; CD246; CD246 antigen; EC 2.7.10.1 Ki 1; Ki1; NBLST3; Tcrz; TFG/ALK; ALK_HUMAN.  

详细介绍:


规格:100ul 
说 明 书100ul  
产品类型磷酸化抗体 
研究领域肿瘤  神经生物学  信号转导  生长因子和激素  激酶和磷酸酶  通道蛋白  
抗体来源Rabbit
克隆类型Polyclonal
交叉反应 Human, Mouse, Rat, Chicken, Cow, Horse, 
产品应用IF=1:50-200  
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量174kDa
性    状Lyophilized or Liquid
浓    度1mg/ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human ALK around the phosphorylation site of Tyr1586
亚    型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

相关资料:


产品介绍background:
This gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This protein comprises an extracellular domain, an hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain. It plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system. This gene has been found to be rearranged, mutated, or amplified in a series of tumours including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer. The chromosomal rearrangements are the most common genetic alterations in this gene, which result in creation of multiple fusion genes in tumourigenesis, including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3), ALK/NPM1 (chromosome 5), ALK/SQSTM1 (chromosome 5), LK/KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (chromosome X).[provided by RefSeq, Jan 2011].

下一条

FITC标记的磷酸化β抑制蛋白1抗体

上一条

FITC标记的NUDT17蛋白抗体

相关信息
扫一扫
直接在手机上打开